Sage Therapeutics (SAGE) PT Raised to $198 at Stifel
Tweet
Share
E-mail
Get Alerts SAGE Hot Sheet
Price: $8.68 --0%
Rating Summary:
3 Buy, 25 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Rating Summary:
3 Buy, 25 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Join SI Premium – FREE
Stifel raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $198.00 (from $105.00) while maintaining a Buy rating.
"Results were notable for clean safety, fast onset and solid durability of effect," Walsh said. "Today's positive results, paired with November's positive P3 brexanolone results (note here) suggest the company's pipeline of proprietary GABAA modulators may offer potential treatment for a range of psychiatric indications."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) PT Raised to $250 at UBS Following Q1 Results
- The Lovesac Co. (LOVE) PT Lowered to $18 at DA Davidson as Guidance Lowered
- Barrington Research Upgrades Copart (CPRT) to Outperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
StifelSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
